You are here

Implantable Electrospun Cell Chamber Device with Immune-Evasive Properties for Beta Cell Replacement Therapy

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43DK137616-01
Agency Tracking Number: R43DK137616
Amount: $275,766.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: 200
Solicitation Number: PA22-176
Timeline
Solicitation Year: 2022
Award Year: 2023
Award Start Date (Proposal Award Date): 2023-09-01
Award End Date (Contract End Date): 2024-08-31
Small Business Information
200 Homer Avenue, Unit 1P
Ashland, MA 01721-1717
United States
DUNS: 131658739
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 PATRICK HAYDEN
 (508) 881-8860
 patrick.hayden@biosurfaces.us
Business Contact
 MATTHEW PHANEUF
Phone: (508) 881-8860
Email: matt.phaneuf@biosurfaces.us
Research Institution
N/A
Abstract

Type 1 diabetes (T1D) is a disease caused by destruction of pancreatic beta cells (-cells) due to an auto-
immune response. T1D exerts a tremendous burden on quality of life for patients, and leads to a wide range of
serious lifelong health consequences. T1D also places a tremendous economic burden on health care systems.
The market for treatment of T1D is expected to reach $29 billion by 2029. Current treatments for T1D include
insulin injections/infusions, pancreas transplant, or transplantation of isolated pancreatic islets of Langerhans for
replacement of -cells. Replacement of the -cells by pancreas or pancreatic islets transplantation is a highly
promising approach to T1D treatment, but is limited by a scarcity of donors. Furthermore, protection of the cells
from the host immune system by immunosuppressive drugs is still required to avoid transplant rejection. To avoid
the need for immunosuppression, efforts have been made to encapsulate isolated islets or -cells in an immune–
protected environment. Although some promising results have been reported, thick fibrotic tissue formation
around the encapsulation device has remained a persistent problem. The fibrotic capsule may block release of
insulin and cause nutrient limitation and hypoxic conditions within the device, leading to -cell death and
subsequent device failure. Furthermore, devices that do not provide adequate immune protection for the
encapsulated cells still require lifelong immunosuppression of patients. This Phase I SBIR proposal will evaluate
a novel electrospun (e-spun) cell chamber (Bio-Spun™ Cell Chamber or BSCC). Due to the unique nanofiber
nature of e-spun materials, the device does not induce thick fibrotic capsule formation following implantation. A
cell barrier layer within the device offers an immune-protected environment that supports growth and long-term
maintenance of cells inside the chambers without immunosuppression. The BSCC device will be loaded with
freshly isolated human pancreatic islets (hPI) containing functional pancreatic -cells, and the BSCC-hPI will be
tested for glucose-stimulated insulin secretion, biocompatibility and efficacy for providing insulin independence
following implantation in a diabetic rat model. The milestone for successful completion of these aims will be
efficacy for providing insulin independence in diabetic rats for 60 days (primary endpoint) and demonstration of
biocompatibility of the BSCC-hPIs with the host animals, including engraftment of heathy, non-fibrotic tissue into
the outer layer of the BSCC device (secondary endpoint). The BSCC-hPI device is expected to overcome two
major shortfalls (i.e., need for lifelong immunosuppression drugs, and lack of biocompatibility of currently
available encapsulation devices) encountered to-date with attempts at -cell replacement therapy. Successful
completion of these aims will demonstrate the feasibility for advancement of the project to more comprehensive
Phase II SBIR biocompatibility and efficacy studies to be conducted in a diabetic porcine model. These will be
followed by human clinical trials, and introduction of the BSCC-hPI device into the clinical marketplace as an
important new treatment option for T1D patients.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government